Immix Biopharma, Inc. (NASDAQ:IMMX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Immix Biopharma, Inc. (NASDAQ:IMMX) has been given an average recommendation of “Moderate Buy” by the six research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $18.25.

A number of research firms have recently issued reports on IMMX. HC Wainwright raised their price target on Immix Biopharma from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, March 27th. Mizuho upped their price objective on Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Monday. Wall Street Zen downgraded Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Finally, Morgan Stanley initiated coverage on Immix Biopharma in a research note on Wednesday, March 25th. They set an “overweight” rating and a $20.00 price target for the company.

Hedge Funds Weigh In On Immix Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP purchased a new stake in Immix Biopharma in the fourth quarter worth about $30,000. Mathes Company Inc. purchased a new position in shares of Immix Biopharma during the 4th quarter valued at about $56,000. Balyasny Asset Management L.P. purchased a new position in shares of Immix Biopharma during the 4th quarter valued at about $67,000. Kera Capital Partners Inc. bought a new position in shares of Immix Biopharma during the 4th quarter valued at approximately $68,000. Finally, Squarepoint Ops LLC bought a new position in shares of Immix Biopharma during the 4th quarter valued at approximately $112,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Immix Biopharma Stock Up 3.7%

Shares of Immix Biopharma stock opened at $8.94 on Friday. Immix Biopharma has a twelve month low of $1.34 and a twelve month high of $11.61. The company’s 50 day moving average is $8.09 and its 200 day moving average is $5.43. The company has a market cap of $473.55 million, a price-to-earnings ratio of -10.04 and a beta of 0.20.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Wednesday, March 25th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.12). Sell-side analysts expect that Immix Biopharma will post -0.87 EPS for the current fiscal year.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.